Lymphoma  >>  Duvyzat (givinostat)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Duvyzat (givinostat) / Italfarmaco
NCT00496431 / 2007-000049-36: phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients

Terminated
2
19
Europe
histone deacetylase inhibitor (ITF2357), Givinostat
Italfarmaco
Hodgkin's Lymphoma
03/09
03/09
NCT00792831 / 2006-005465-19: Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Terminated
2
3
Europe
ITF2357, Givinostat
Italfarmaco
Chronic Lymphocytic Leukemia
04/09
04/09
NCT00792467 / 2007-007091-41: Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Completed
2
24
Europe
ITF2357, Givinostat, histone deacetylase inhibitor
Italfarmaco
Hodgkin's Lymphoma
07/10
09/10
2006-002113-12: Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects aged over 60 years with primary or secondary DLBCL refractory/ relapsed after conventional chemotherapy with or without prior immunotherapy

 
2
23
Europe
ITF2357,
ITALFARMACO
Primary or secondary DLBCL refractory/relapsed after conventional chemotherapy
 
 

Download Options